Pod Insights Finshots Daily Understanding the Gaudium IVF IPO About this episode In today’s episode on 20th Feb 2026, we break down the Gaudium IVF and Women Health IPO, which opened for subscription today and closes on 24th February 2026 (Tuesday).
Book a FREE call with Ditto https://ditto.sh/vx51ji
https://ditto.sh/vx51ji
Transcript 0:01 Speaker 00 Hello folks, you're tuned in different shots daily. In today's episode, we break down the Gaudium IVF and Women Health IPO, which opened for subscription today and closes on 24th Feb 2026, that is Tuesday.
0:16 Speaker 00 Before we begin, here's a quick word from team Ditto. Life can be unpredictable and if the main earner is not around, the bills won't stop. That's why term insurance is so important. It gives your family a fixed payout so they can cover school fees, EMIs and daily expenses without stress. If you buy it early, you can get a one crore cover for as little as thousand rupees a month and the premium stays the same for your entire policy term. That's real peace of mind at a very small cost. And if you're not sure which plan is right for you, book a free call with Ditto. No spam, just honest guidance and we're trusted by over 8 lakh people for their health and term insurance needs. Now, back to the story.
0:58 Speaker 00 In 2003, India's fertility rate stood at 3.1 births per woman. Now cut to 2023 and it's down to 2. The fertility rate simply means the average number of children a woman would have over her lifetime. Assuming she lives through her reproductive years, that's typically between 15 to 49. Now, two children per woman might sound perfectly reasonable, but here's the catch. To keep a population stable, the rate needs to be at least 2.1. That's what the demographers call the replacement level. And that tiny 0.1 gap actually matters because when you compound that shortfall across millions of families, it means fewer young people entering the workforce in the future and a larger elderly population to support.
1:41 Speaker 00 And over time, that shift can weigh on economic growth. And the reasons behind this decline aren't exactly surprising. Urban couples today are prioritizing education and careers before marriage and children. At the same time, medical advances like egg freezing and IVF, where an egg is fertilized with sperm outside the body in lab conditions, that's basically what in vitro fertilization is. Well, these have made people more comfortable delaying parenthood in the first place. Besides, rising incomes and even EMI financing. Thinking for fertility treatments which can cost several lakhs of rupees by the way, have made assisted reproduction more accessible beyond just big cities. Add to that, modern lifestyles that include long sitting hours,
2:22 Speaker 00 stress, smoking, alcohol and other factors contributing to infertility among both men and women. Put all this together and you can see why assisted reproductive technology or what we call as art has become one of the fastest growing segments in healthcare. For context, the global IVF market was about twenty seven billion dollars in twenty twenty four and is expected to double to fifty four billion dollars by twenty thirty four. India's market, though smaller at roughly one billion dollars, could quadruple in the same period. And that's the backdrop against which Guardian IVF and Women Health now plans a one sixty five crore rupees IPO. If it pulls this off, it would become the first pure play fertility services company in India to hit the stock market.
3:04 Speaker 00 So, let's understand Guardian IVF's business model and whether it's worth the money it's asking for. But for that, we'll have to give you a fair idea of what IVF clinics actually do in the first place. At its simplest, you can think of an IVF clinic as a specialty hospital for people who can't conceive naturally. The process itself is fairly structured. Doctors stimulate the ovaries, the organs that store and release eggs, using hormones. They then retrieve the eggs, select the healthiest sperm from the partner or a donor sample, fertilize the egg in a lab and create embryos, the early stage of a developing baby formed from a fertilized egg. These embryos are grown for three to five days before one or more are transferred onto the uterus. Then comes the longest two-week wait for a pregnancy test.
3:47 Speaker 00 Now, that's the core service around which IVF clinics build their revenue. First, there's fertility treatment, the biggest bucket by far. This includes IVF, but it doesn't stop there. It also covers male infertility treatment, I U I or intrauterine insemination, where sperm is placed directly inside the uterus to improve chances of conception. I C S I or intra-sto-plastemic sperm injection, often combined with IVF for male fertility issues, ovulation induction to stimulate egg release, surrogacy, infertility surgeries and treatment for PC.
4:20 Speaker 00 That's polycystic ovary syndrome. In Gaudium's case, the segment contributed seventy-nine percent of total operating revenue in FI twenty-five. Next are hospital services, contributing about five percent. Gaudium runs a fifteen-bed hospital in Janappuri, Delhi NCR, which is also where it is based out of. It handles daycare procedures related to women's and child's health, IVF treatments, and even deliveries for patients who choose to have their babies there. Now, we know what you're thinking, just one hospital in Delhi sounds limited, but Gaudium doesn't rely on a single location. It follows a hub-and-spoke model, meaning it operates seven main hubs across Delhi, which has two centers, Mumbai, Ludhiana, Srinagar, Patna, and Bangalore. These are full-service centers, by the way, where advanced procedures are carried out.
5:03 Speaker 00 Around these hubs, Gaudium has built a network of twenty-eight spoke centers and alliances with infertility clinics in smaller towns. These handle consultations, preliminary treatments, and follow-ups. Only patients who need advanced care are referred to the hubs or to the hospital for daycare procedures. These locations are deliberately chosen in states where fertility rates are below one-point-eight. This model helps Gaudium stay asset-light, expand its reach, and grow without having to pour massive capital into building hospitals everywhere. Finally, there's pharmacy services, contributing sixteen percent of revenue. The in-house pharmacy supplies medicines and consumables for treatments and supports other centers. Together, this translated into seventy crore rupees in operating revenue in FI twenty-five, growing at twenty-six-point-five CAGR over two years.
5:48 Speaker 00 Profits rose from thirty crore rupees in FI twenty-three to nineteen crore rupees in FI twenty-five. EBITDA margins remained strong at forty, forty-five percent, while PAT margins dipped from thirty percent in FI twenty-three to twenty-one percent in FI twenty-four, before recovering to twenty-six percent in FI twenty-five. Now, that might sound odd, revenue and EBITDA have gone up, so why are profit margins under pressure? The answer lies in something called average revenue per person, or ARPP. This fell sharply from three-point-four-four lakh rupees in FI twenty-three to one-point-eight-nine lakh rupees in FI twenty-four, before bouncing back to three-point-five-five lakhs in FI twenty-five. The reason is fairly simple, an IBF cycle is in a single event.
6:30 Speaker 00 It's a series of stages, ovarian stimulation, oocyte pickup or OPU where mature eggs are retrieved, fertilization in a lab happens, embryo development happens, embryo transfer and finally the pregnancy test. And not all stages earn the same money by the way. The ET stage typically brings in higher realizations and better margins, but in the earlier stages, especially OPU, the clinic incurs heavy costs on medication and consumables. And over the past years, OPU cycles have increased from 1,167 in FI 23 to 1,00563 in FI 25. Meanwhile, ED cycles have actually fallen from 2,345 to 1,913. So more revenue came from relatively lower margin stages. Add to that the fact that total expenses as a percentage of revenue rose from 58% to 64%
7:14 Speaker 00 and you can see why margins took a hit. That said, even with this blip, Guardian's profitability still stands out. Its PAT margin of 26% is comfortably higher than unlisted peer Indira IVF which operates at around 18%. It's also ahead of global players like Progeny in New York at 4 to 5% and Inspire IVF in Bangkok at 15 to 20%. Another advantage for Guardian IVF comes from tighter regulations. In recent years, India has made its surrogacy and art laws fast acter. Commercial surrogacy has been banned. Now only married women who already have at least one biological child and other relatives of the intended parents can act as surrogates. Embryo trading and sex selection are banned too. This has reshaped the industry.
7:55 Speaker 00 What was once a largely unregulated space dominated by small clinics is gradually moving towards organized, compliant chains that can handle stricter oversight. That naturally favors scaled players like Guardian IVF, especially with its hub and spoke model. Now sure, tougher rules have reduced some of the earlier medical tourism, particularly around commercial surrogacy, but India still enjoys a strong cost advantage. An IVF cycle here costs about $3,000 to $4,000 versus $15,000 to $20,000 in the US and that price gap keeps India attractive to foreign patients, giving Guardian IVF another structural edge. But that said, there are a few things you should think about before deciding whether this IPO is worth betting on. First, success rate, arguably the most important metric in this business. Guardian IVF claims a success rate of 58%. Now that, by the way,
8:40 Speaker 00 solid but peers like Indra IVF and Inspire IVF report success rates over seventy percent. Now in a space where outcomes matter more than branding, now that gap is hard to ignore. Second, there is a sizable contingent liability, that is a potential financial liability that may or may not occur depending on the outcome of the case. And that's of the size of forty-four crore rupees tied to direct tax proceedings. Now to put that in perspective, that's roughly seventy-six percent of the company's net worth of fifty-eight crore rupees as of September twenty twenty-five. Now, the promoter, Dr. Manika Khanna, who is also the founder, has formally undertaken that if this liability materializes and the company can't meet it, she will infuse funds through unsecured debt or equity. That offers some comfort, but it's still a risk that you can't ignore.
9:23 Speaker 00 And then there's a small contradiction in how it plans to use the IPO money. Of the ninety crore rupees that Guardian IVF will raise through a fresh issue of shares, fifty crore rupees will go towards setting up new IVF centers, twenty crores to repay debt and the rest for general corporate purposes. But remember, Guardian's key strength, something it has also highlighted in its RHP, has been its asset-light hub-and-spoke model. So, expanding physical centers more aggressively feels slightly at odds with that narrative. Plus, expanding while dealing with a high employee attrition rate of sixty-three percent and relying on just five embryologists to support a growing business seems like another red flag. As for the evaluation, it's hard to evaluate whether the five seventy-five crore rupees it's commanding is fair,
10:06 Speaker 00 since there isn't a listed peer in India to compare it with. But if you look at the industry average among global listed companies, at the upper end of its offer price band of seventy-nine rupees, Guardian IVF trades at a P of twenty-five. That's almost at par with the global industry average of around twenty-six. So, yes, that's pretty much all there was to unpack about the Guardian IVF IPO. And while it may not be a name you hear every day, it definitely gave us a good excuse to break down how India's IVF industry actually works. And we'll only have to wait and see whether this IPO has a healthy success rate of its own. All right, I'll see you in the next one. Have a happy weekend.
10:41 Speaker 00 Thank you for listening to today's episode. And if you want to share your feedback or suggestions, do drop us an email to [email protected] . Until next time.
Previous Why can’t the world replace China? Next Can we regulate attention? Page updated November 10, 2026 · transcript and summary are machine-generated